Encyclopedia · Metabolic & Weight Loss

SLU-PP-332

Evidence review

Evidence grade D

Evidence is primarily from animal and laboratory studies; human efficacy and an established dose are absent.

Reviewed Aug 10, 2026 2 linked authoritative sources

Despite the legacy URL and online marketing category, SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors, not an amino-acid peptide. It is a laboratory chemical probe with no FDA-approved product, indication, or human dose.

SLU-PP-332 is not a peptide

Despite the legacy URL and online marketing category, SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors, not an amino-acid peptide. It is a laboratory chemical probe with no FDA-approved product, indication, or human dose.

“Exercise mimetic” refers to mouse experiments

In mice, SLU-PP-332 increased oxidative muscle-fiber features and exercise endurance through ERRα-dependent signaling.[1] A later study in mouse models of obesity reported lower fat mass and improved metabolic measures.[2] These studies did not test people, and “exercise mimetic” does not mean the compound reproduces the cardiovascular, musculoskeletal, neurological, or mortality benefits of exercise.

Human safety and efficacy are unknown

There is no controlled human exposure program, clinical pharmacokinetic profile, adverse-reaction table, validated dose, pregnancy information, interaction assessment, or long-term carcinogenicity evidence. Online claims about fat loss, endurance, or a pill that replaces exercise go beyond the published evidence.

Regulatory status

SLU-PP-332 is an unapproved research compound in the United States. Teloryx does not publish a human dose, cycle, stack, or preparation protocol.

Evidence review

Sources and evidence

Citation numbers in the article link to the exact regulator records, trial registrations, and publications reviewed.

  1. ACS Chemical BiologySynthetic ERR agonist induces an acute aerobic exercise response in mice (2023)
  2. Journal of Pharmacology and Experimental TherapeuticsA synthetic ERR agonist alleviates metabolic syndrome in mice (2023)